MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS.
Objective: Differentiated thyroid cancer patients uncommonly present with bone metastasis as initial manifestation. Their molecular profile is largely unknown. The aim of this study was to evaluate histopathology, molecular profiles, and response to radioactive iodine therapy in these patients. Methods: Eight patients presented with symptomatic bone metastasis from an unknown primary tumor. We identified these patients by performing a retrospective chart review. Pathology slides were reviewed and molecular analysis of 112 thyroid cancer-related genes was performed on bone metastasis specimens using targeted next-generation sequencing, ThyroSeq v3 assay. Results: These patients presented with long bone fractures, spinal cord compression, or intractable bone pain. Histopathological analysis of the bone and thyroid tumor specimens revealed follicular variant of papillary carcinoma in seven patients and tall cell variant papillary carcinoma in one. Primary tumor size ranged from 0.4 to 7.5 cm. All patients received high dose radioiodine therapy following thyroidectomy. Molecular analysis revealed TERT mutations in seven (88%) tumors, four (50%) contained co-occurring TERT and RAS, two had isolated TERT, and one with TERT and BRAF V600E mutations respectively. Tumors carrying RAS, TERT or a combination of these mutations were radioiodine-avid, with predictable tumor response and reduction in serum thyroglobulin levels. One patient with radioiodine-refractory disease harbored BRAF and TERT mutations. Conclusion: These results demonstrate that differentiated thyroid cancers presenting with bone metastasis independent of the primary tumor size have a high prevalence of TERT mutations, frequently coexisting with RAS mutations. This molecular signature may predict a favorable response to radioiodine therapy.